Kupffer Cell TMEM16F: A Central Regulator of Liver Defense in Listeria Infection

Study Background and Research Question

Bacterial pathogens such as Listeria monocytogenes cause significant morbidity and mortality worldwide, with liver-resident macrophages (Kupffer cells, KCs) playing a frontline role in immune defense. Previous studies have shown that pore-forming toxins from pathogens can disrupt plasma membrane (PM) integrity, necessitating rapid repair mechanisms to avert cell death and immunopathology. TMEM16F, a calcium-activated lipid scramblase, has emerged as a key player in PM repair and immune regulation, but its cell-type specific functions during bacterial infection in vivo remained unresolved. The central research question of this study was: In which immune cell population is TMEM16F expression essential for host protection against Listeria monocytogenes, and by what mechanisms?

Key Innovation from the Reference Study

The study by Tang et al. (Advanced Science, 2024) provides a decisive advance by using immune cell type-specific TMEM16F-deficient mouse models to pinpoint Kupffer cell-expressed TMEM16F as the critical determinant of liver protection during Listeria infection. Unlike previous work that highlighted TMEM16F's role in T cell membrane repair, this research demonstrates that KC-specific deletion of TMEM16F—not T cell or B cell deletion—renders mice highly susceptible to infection, liver necrosis, and metabolic dysregulation. The mechanistic link is the lipid scrambling activity of TMEM16F, which enables rapid PM repair in Kupffer cells, preventing necrotic cell death and dampening excessive inflammation.

Methods and Experimental Design Insights

The authors generated and rigorously characterized conditional TMEM16F knockout mice, targeting TMEM16F deletion specifically to Kupffer cells, T cells, or B cells. Following systemic Listeria monocytogenes challenge, they assessed survival, bacterial burden, liver histopathology, KC viability, and metabolic parameters. PM integrity and repair capacity were evaluated using both in vivo and ex vivo models, including exposure to the Listeria-derived pore-forming toxin listeriolysin O (LLO). Lipid scrambling activity was monitored via established fluorescence-based assays, and inflammatory cytokine profiles were quantified.

Core Findings and Why They Matter

• Kupffer cell TMEM16F is indispensable for host survival and liver protection during Listeria infection. Mice lacking TMEM16F in KCs—but not in T or B cells—exhibited greater mortality, higher hepatic bacterial loads, and pronounced liver necrosis (Tang et al., 2024).
• TMEM16F enables rapid plasma membrane repair in KCs. Without TMEM16F, KCs were highly susceptible to PM rupture and fragmentation upon LLO exposure, resulting in necrotic cell death—an event closely tied to the release of pro-inflammatory mediators and tissue injury.
• Loss of TMEM16F in KCs amplifies inflammation and disrupts liver metabolism. TMEM16F-deficient KCs failed to contain inflammation, as evidenced by upregulated cytokine production and pathological metabolic signatures in the liver.
• Cell death in this context exhibits features of programmed necrotic cell death, including necroptosis. While not directly dissected in this study, these findings resonate with the broader literature on necroptosis inhibition as a protective strategy in tissue injury (internal article).

These results clarify that membrane repair, orchestrated by TMEM16F lipid scrambling in KCs, is a linchpin in the hepatic response to bacterial toxins, with direct consequences for inflammation and metabolic homeostasis.

Comparison with Existing Internal Articles

Several recent articles have explored TMEM16F’s broader role in regulated cell death pathways. For example, Yang et al. (2025) and related reviews (internal resource) describe how TMEM16F-mediated lipid scrambling suppresses ferroptosis, another form of regulated necrosis, and modulates immune responses in cancer. While these studies focus on tumor immunity and ferroptosis, Tang et al. extend the significance of TMEM16F to antibacterial defense, specifically by preventing necroptotic or necrosis-like death in liver macrophages. This complements prior work on Necrostatin 2 (Nec-2) as a selective RIPK2 inhibitor for necroptosis inhibition workflows, highlighting the convergence of membrane repair and cell death pathway modulation in controlling tissue injury.

Limitations and Transferability

While the study provides compelling genetic and functional evidence for TMEM16F’s role in Kupffer cells, several limitations are noted. First, the work focuses on acute Listeria infection in mice; extrapolation to other pathogens or chronic inflammatory settings requires further investigation. Second, although necroptosis and related pathways are implicated, the precise molecular crosstalk between TMEM16F-mediated repair and necroptotic signaling was not dissected in this model. Future studies may benefit from parallel use of necroptosis pathway inhibitors, such as Necrostatin 2, to parse these interactions. Furthermore, species differences in immune architecture and TMEM16F regulation should be considered when translating these findings to human disease.

Protocol Parameters

• Conditional knockout model: Use immune cell lineage-specific Cre recombinase drivers to delete TMEM16F in Kupffer cells (e.g., Clec4f-Cre), T cells (Cd4-Cre), or B cells (Cd19-Cre).
• Listeria challenge: Intravenous administration of Listeria monocytogenes at 1–2 × 10⁴ CFU per mouse for acute infection studies.
• Plasma membrane repair assays: Apply LLO (Listeria-derived toxin) to isolated KCs or liver sections; assess PM integrity by propidium iodide uptake or live/dead cell staining.
• Lipid scrambling activity: Measure using NBD-labeled phospholipid probes and flow cytometry or fluorescence microscopy.
• Cytokine profiling and metabolic analysis: Perform multiplex ELISA and targeted metabolomics from liver homogenates post-infection.
• Necroptosis pathway inhibition (literature recommendation): For studies dissecting the contribution of programmed necrotic cell death, consider parallel treatment with necroptosis inhibitors such as Necrostatin 2 or genetic deletion of RIPK kinases, as outlined in internal workflow guides.

Research Support Resources

For researchers aiming to model necroptosis inhibition and dissect the interplay between plasma membrane repair and programmed necrotic cell death, the use of Necrostatin 2 (Nec-2) (SKU A3652) is supported by the latest workflow guides. Nec-2 is a potent small-molecule inhibitor of RIPK2, making it a valuable tool for mechanistic studies of necroptosis and inflammation in hepatic and infection models. Product protocols recommend using freshly prepared solutions and maintaining storage at -20°C for optimal stability. Researchers can obtain Nec-2 from APExBIO to complement genetic models or pharmacological studies in cell death research.